# Haemonetics (HAE) — Earnings

HAE · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/hae/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q1 2027 |
| Period end | Jun 27, 2026 |
| EPS actual | $1.14 |
| EPS estimate | $1.08 |
| EPS surprise | +5.87% |
| Revenue surprise | +3.51% |
| Revenue | $339.4M |
| Revenue estimate | $327.9M |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/313143/000031314326000120/hae-20260627.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/8cef4fa3-0d33-7a27-75b3-7e1e55d455ea.html) |

Haemonetics reported fiscal Q1 2027 results, for the quarter ended June 27, 2026, on August 6, 2026. Earnings per share were $1.14, ahead of the $1.08 estimate by 5.87%. Revenue was $339.4 million, 3.51% above the $327.9 million consensus. Compared with fiscal Q1 2026, EPS rose about 4% from $1.10 and revenue rose about 6% from $321.4 million.

Earnings have climbed steadily over the table. Annual EPS rose from $3.03 in fiscal 2023 to $3.98 in fiscal 2024, $4.57 in fiscal 2025 and $4.97 in fiscal 2026, about 64% higher over three years. Revenue has not kept pace recently: fiscal 2026 revenue was $1.33 billion, about 2% below the $1.36 billion of fiscal 2025. The highest quarterly EPS in the table is $1.31, from fiscal Q3 2026. Haemonetics has a consistent record against estimates. Over the last 20 quarters it topped the EPS estimate 19 times, and the only miss was fiscal Q2 2022, at 0.96% below.

Haemonetics reported fiscal Q2 between November 2 and November 9 in each of the past five years. That points to early November 2026 for the next report. It will show whether the year-over-year earnings growth seen in recent quarters continues into fiscal 2027.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q1 2027 | Aug 6, 2026 | $1.08 | $1.14 | 5.87% | $327.9M | $339.4M |
| Q4 2026 | May 7, 2026 | $1.27 | $1.29 | 1.37% | $336.8M | $346.4M |
| Q3 2026 | Feb 5, 2026 | $1.25 | $1.31 | 4.83% | $331.9M | $339.0M |
| Q2 2026 | Nov 6, 2025 | $1.11 | $1.27 | 14.44% | $311.5M | $327.3M |
| Q1 2026 | Aug 7, 2025 | $1.01 | $1.10 | 9.11% | $301.8M | $321.4M |
| Q4 2025 | May 8, 2025 | $1.22 | $1.24 | 1.65% | $329.4M | $330.6M |
| Q3 2025 | Feb 6, 2025 | $1.17 | $1.19 | 1.37% | $352.7M | $348.5M |
| Q2 2025 | Nov 7, 2024 | $1.07 | $1.12 | 4.36% | $342.6M | $345.5M |
| Q1 2025 | Aug 8, 2024 | $1.01 | $1.02 | 1.44% | $335.1M | $336.2M |
| Q4 2024 | May 9, 2024 | $0.89 | $0.90 | 0.92% | $329.5M | $343.3M |
| Q3 2024 | Feb 8, 2024 | $0.94 | $1.04 | 10.46% | $320.8M | $336.3M |
| Q2 2024 | Nov 2, 2023 | $0.89 | $0.99 | 11.51% | $313.2M | $318.2M |
| Q1 2024 | Aug 8, 2023 | $0.72 | $1.05 | 45.25% | $292.7M | $311.3M |
| Q4 2023 | May 11, 2023 | $0.70 | $0.77 | 9.33% | $290.8M | $304.4M |
| Q3 2023 | Feb 7, 2023 | $0.82 | $0.85 | 4.06% | $299.6M | $305.3M |
| Q2 2023 | Nov 7, 2022 | $0.67 | $0.83 | 23.18% | $269.2M | $297.5M |
| Q1 2023 | Aug 10, 2022 | $0.51 | $0.58 | 13.73% | $249.0M | $261.5M |
| Q4 2022 | May 10, 2022 | $0.60 | $0.65 | 8.24% | $257.1M | $265.0M |
| Q3 2022 | Feb 8, 2022 | $0.73 | $0.85 | 15.18% | $265.4M | $259.8M |
| Q2 2022 | Nov 9, 2021 | $0.61 | $0.60 | -0.96% | $240.8M | $239.9M |

## Frequently Asked Questions

### When did Haemonetics (HAE) last report earnings?

Haemonetics last reported on Aug 6, 2026, covering fiscal Q1 2027.

### Did HAE beat earnings estimates?

Yes. Haemonetics reported EPS of $1.14 for Q1 2027 against a $1.08 estimate — a 5.87% beat.

### How much revenue did HAE report last quarter?

Haemonetics reported $339.4M in revenue for Q1 2027, against a consensus estimate of $327.9M.

## Similar Stocks

- [PODD](https://www.lighthorse.io/tickers/podd) — Insulet Corporation - Common Stock
- [DXCM](https://www.lighthorse.io/tickers/dxcm) — DexCom, Inc. - Common Stock
- [QTRX](https://www.lighthorse.io/tickers/qtrx) — Quanterix Corporation - Common Stock
- [SIBN](https://www.lighthorse.io/tickers/sibn) — SI-BONE, Inc. - Common Stock
- [PEN](https://www.lighthorse.io/tickers/pen) — Penumbra, Inc. Common Stock
- [ZBH](https://www.lighthorse.io/tickers/zbh) — Zimmer Biomet Holdings, Inc. Common Stock
- [HQY](https://www.lighthorse.io/tickers/hqy) — HealthEquity, Inc. - Common Stock
- [LNTH](https://www.lighthorse.io/tickers/lnth) — Lantheus Holdings, Inc. - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).